Nasus Pharma has appointed pharmaceutical industry veteran Brendan P. O'Grady as its new Chief Executive Officer, effective July 27, 2026. O'Grady succeeds Dan Teleman and will focus on unlocking the commercial potential of NS002, the company's lead intranasal epinephrine candidate for anaphylaxis, which targets a $2 billion market. The company plans to advance NS002 into a pivotal trial in the fourth quarter of 2026, with topline data expected in the first quarter of 2027. O'Grady brings over three decades of experience, including 21 years at Teva Pharmaceuticals where he rose to CEO of Teva USA, and most recently served as CEO of Assertio Holdings.
Nasus Pharma Ltd.Appointment of experienced CEO to lead strategic growth and advance NS002 into pivotal trial.
Assertio Therapeutics Inc
Teva Pharma Industries Ltd ADR